Početna › Kronična limfocitna leukemija
Kliničke studije za Kronična limfocitna leukemija koje traže sudionike u SAD-u
120 studija za Kronična limfocitna leukemija traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Boston, MA31 studija
- Columbus, OH28 studija
- Durham, NC27 studija
- Washington, DC22 studija
- Seattle, WA20 studija
- Rochester, MN19 studija
- New York City, NY18 studija
- Houston, TX17 studija
- Baldwin Park, CA16 studija
- Milwaukee, WI15 studija
- Cincinnati, OH14 studija
- Chicago, IL14 studija
- Nashville, TN13 studija
- Jacksonville, FL11 studija
- Philadelphia, PA11 studija
- Atlanta, GA11 studija
- Dallas, TX10 studija
- Portland, OR10 studija
- Salt Lake City, UT10 studija
- Kansas City, MO10 studija
- San Diego, CA10 studija
- Pittsburgh, PA10 studija
- Denver, CO9 studija
- Charlotte, NC9 studija
- Miami, FL9 studija
- St. Louis, MO8 studija
- Los Angeles, CA8 studija
- Winston-Salem, NC8 studija
- Queens, NY8 studija
- Omaha, NE8 studija
- Des Moines, IA8 studija
- Tampa, FL8 studija
- Cleveland, OH8 studija
- Minneapolis, MN8 studija
- Clifton, NJ7 studija
- Mountain View, CA7 studija
- Cedar Rapids, IA7 studija
- Aurora, CO7 studija
- Fort Wayne, IN7 studija
- Detroit, MI7 studija
Po državama
- Alabama7 studija
- Arizona15 studija
- Arkansas4 studija
- Colorado17 studija
- Connecticut4 studija
- Delaware4 studija
- Distrikt Columbia4 studija
- Florida34 studija
- Georgia16 studija
- Idaho4 studija
- Illinois17 studija
- Indiana12 studija
- Iowa10 studija
- Kalifornija33 studija
- Kansas6 studija
- Kentucky7 studija
- Louisiana6 studija
- Maine6 studija
- Maryland23 studija
- Massachusetts33 studija
- Michigan12 studija
- Minnesota29 studija
- Mississippi5 studija
- Missouri13 studija
- Montana7 studija
- Nebraska8 studija
- Nevada6 studija
- New Hampshire3 studija
- New Jersey13 studija
- New Mexico3 studija
- New York26 studija
- North Carolina34 studija
- Ohio43 studija
- Oklahoma4 studija
- Oregon16 studija
- Pennsylvania22 studija
- Rhode Island6 studija
- South Carolina5 studija
- South Dakota3 studija
- Tennessee17 studija
- Texas38 studija
- Utah10 studija
- Virginia12 studija
- Washington26 studija
- Wisconsin19 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
U tijeku regrutacijaOpažajna studija
Od 18 do 110 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
U tijeku regrutacijaFaza 1
Do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
U tijeku regrutacijaFaza 2
Od 75 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
U tijeku regrutacijaOpažajna studija
Od 18 do 110 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
U tijeku regrutacijaFaza 2
Od 18 do 85 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.